Arthur Tzianabos - 01 Jan 2024 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)

Role
Director
Signature
/s/ Paul Alloway, Attorney-in-Fact for Arthur O. Tzianabos
Issuer symbol
QTTB
Transactions as of
01 Jan 2024
Net transactions value
-$7,445
Form type
4
Filing time
15 Feb 2024, 16:33:43 UTC
Previous filing
15 Jun 2023
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FIXX Common Stock Options Exercise +14,280 +13% 122,675 01 Jan 2024 Direct F1
transaction FIXX Common Stock Options Exercise +19,140 +16% 141,815 01 Jan 2024 Direct F1
transaction FIXX Common Stock Sale $7,445 -13,037 -9.2% $0.5711 128,778 09 Jan 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FIXX Restricted Stock Units Options Exercise $0 -14,280 -100% $0.000000* 0 01 Jan 2024 Common Stock 14,280 Direct F1, F4
transaction FIXX Restricted Stock Units Options Exercise $0 -19,140 -49% $0.000000 19,720 01 Jan 2024 Common Stock 19,140 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
F3 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5710 to $0.5712. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
F4 The RSUs are fully vested and do not have an expiration date.
F5 The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.